Blackhill Capital Inc. Cuts Stock Position in Zoetis Inc. $ZTS

Key Points

• Blackhill Capital reduced its Zoetis stake by 28.8% in the second quarter, selling 27,603 shares and retaining 68,296 shares valued at approximately $4.9 million. Zoetis represents about 0.2% of the firm’s portfolio, while institutional investors collectively own 92.8% of the stock.
• Zoetis reported quarterly EPS of $1.87, slightly exceeding analyst expectations of $1.85, but revenue of $2.47 billion fell short of the $2.50 billion estimate and declined 0.2% year over year.
• The stock opened at $77.45, near its 12-month low of $71 and well below its 12-month high of $156.49. Analysts have an average “Hold” rating and a consensus price target of $107.43 after several firms lowered their targets.

Blackhill Capital Inc. cut its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 28.8% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 68,296 shares of the company's stock after selling 27,603 shares during the quarter. Zoetis accounts for approximately 0.2% of Blackhill Capital Inc.'s holdings, making the stock its 20th biggest position. Blackhill Capital Inc.'s holdings in Zoetis were worth $4,908,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ZTS. Prosperity Bancshares Inc acquired a new stake in Zoetis in the fourth quarter valued at about $25,000. Cassaday & Co Wealth Management LLC acquired a new position in Zoetis during the 1st quarter worth approximately $28,000. Elyxium Wealth LLC purchased a new position in shares of Zoetis during the 4th quarter worth approximately $32,000. Root Financial Partners LLC raised its stake in shares of Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company's stock worth $30,000 after buying an additional 103 shares in the last quarter. Finally, Wellington Grp LLC lifted its holdings in shares of Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company's stock valued at $32,000 after buying an additional 267 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Performance

NYSE:ZTS opened at $77.45 on Friday. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The company has a market capitalization of $32.00 billion, a P/E ratio of 12.76, a price-to-earnings-growth ratio of 1.75 and a beta of 0.74. The firm has a 50-day moving average price of $75.57 and a two-hundred day moving average price of $95.62. Zoetis Inc. has a twelve month low of $71.00 and a twelve month high of $156.49.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company's revenue for the quarter was down .2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ZTS. Citigroup cut their price objective on Zoetis from $112.00 to $96.00 and set a "buy" rating for the company in a research report on Tuesday, August 11th. BNP Paribas Exane decreased their target price on shares of Zoetis from $146.00 to $110.00 and set an "outperform" rating on the stock in a research report on Tuesday, August 11th. TD Cowen lowered their price target on shares of Zoetis from $104.00 to $94.00 and set a "buy" rating on the stock in a research note on Tuesday. Barclays cut their price target on shares of Zoetis from $136.00 to $85.00 and set an "equal weight" rating for the company in a report on Wednesday, July 1st. Finally, Wall Street Zen cut shares of Zoetis from a "buy" rating to a "hold" rating in a research note on Saturday, May 2nd. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $107.43.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source